利妥昔单抗治疗类风湿关节炎的实践要点
综述总结利妥昔单抗治疗类风湿关节炎中完全B细胞耗竭与临床应答相关,低治疗前浆母细胞计数、合用改善病情抗风湿药、无吸烟暴露、抗瓜氨酸化蛋白抗体或类风湿因子阳性及低干扰素特征可预测完全B细胞耗竭和临床应答;部分患者再次输注后失去应答但多数后续周期可恢复,减量方案初步结果支持用于维持治疗,需监测IgG浓度。
要点
- 完全B细胞耗竭与利妥昔单抗临床应答及长期维持治疗相关。
- 低浆母细胞计数、合用DMARDs、无吸烟、ACPA/RF阳性、低干扰素特征预测完全耗竭和应答。
- 半数初始完全耗竭且应答者后续输注失去应答,但四分之三在下一周期恢复。
核心结论
- 利妥昔单抗治疗后完全B细胞耗竭与临床应答相关,并有助于长期维持治疗。
研究设计与样本
- 本文为PubMed收录的Lancet Rheumatol综述,检索范围未在摘要中报告。
主要发现
- 低治疗前浆母细胞计数、合用改善病情抗风湿药、无吸烟暴露、抗瓜氨酸化蛋白抗体或类风湿因子阳性及低干扰素特征均预测完全B细胞耗竭和临床应答。
- 半数初始完全B细胞耗竭且临床应答的患者在后续输注后失去应答,但其中四分之三在下一治疗周期恢复。
- 减量利妥昔单抗疗效正在研究中,初步结果提示减量策略最好用于维持治疗,尤其适用于发生不良事件或感染高风险患者。
- 输注相关反应是利妥昔单抗治疗最常见的不良事件,监测IgG浓度至关重要,低浓度与感染风险增加相关。
临床怎么用
- 对类风湿关节炎患者使用利妥昔单抗时,可参考低浆母细胞计数、合用DMARDs、无吸烟、ACPA/RF阳性及低干扰素特征预测完全B细胞耗竭和临床应答。
- 对初始完全B细胞耗竭且应答后失去应答者,可考虑再次治疗,因多数患者下一周期可恢复应答。
- 减量利妥昔单抗策略宜用于维持治疗,尤其适用于发生不良事件或感染高风险患者。
- 治疗期间应监测IgG浓度,因低浓度与感染风险增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell depletion therapy is an effective option for the treatment of rheumatoid arthritis but often does not result in complete B-cell depletion. Complete B-cell depletion after rituximab treatment is associated with clinical response, and this outcome leads to long-term maintenance of therapy. Low pretreatment plasmablast counts, concomitant treatment with disease-modifying antirheumatic drugs, no smoking exposure, the presence of anticitrullinated protein antibodies or rheumatoid factor, and a low interferon signature are all predictive of complete B-cell depletion and clinical response. Half of patients who initially show complete B-cell depletion and clinical response after rituximab treatment eventually lose responsiveness with further infusions. However three-quarters of these patients regain this outcome in their following treatment cycle, suggesting that loss of response is reversible and that patients can still benefit from rituximab retreatment. The efficacy of reduced doses of rituximab is being investigated, but preliminary results suggest that these strategies are best used for maintenance therapy, particularly in patients who suffer adverse events or who are at a high risk of infection. Infusion-related reactions are the most common adverse events associated with rituximab treatment, and monitoring of IgG concentrations is crucial, as low concentrations are correlated with an increased risk of infection.
引用
- Garcia-Montoya L, Villota-Eraso C, Yusof MYM, et al. Lessons for rituximab therapy in patients with rheumatoid arthritis. Lancet Rheumatol. 2020. PMID: 38273611. doi:10.1016/S2665-9913(20)30033-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。